


## Monash Absolute Investment Fund

(APIR MON0001AU)







Long/Short Australian Equities



Proven Track Record<sup>1</sup>

### **March 2023 Fund Update**

In March, the Fund fell 0.9% (after fees). This compares to a decrease of 0.2% for the S&P/ASX200 and a fall of 0.7% for the Small Ords.

Following on from the reporting season month of February, March was a relatively quiet month with little news from our companies.

Our best contributor for the month was REA Group (realestate.com.au ASX: REA) which rose by 12%. REA made no stock exchange announcement this month, but an improvement in property prices was widely reported in the media.

Australian house prices recorded their first rise in 11 months, with capital city values appreciating by 0.6% in March. The falls had bottomed out in February with a modest decline of only 0.1%. Sydney led the gains in March at 1.4%, followed by Melbourne at .6%.

Speculation by commentators of a pause in RBA interest rate rises towards the end of the month perhaps also helped. The RBA had increased interest rates 10 times in a row for a total rise of 3.5%, so a pause to give some time for previous increases to work their way through the economy, and to assess their full impact before adding further rises, was already overdue.

REA is one of the highest quality businesses listed on the ASX, operating an essential service for the residential property market within an effective duopoly and given its strong pricing power. Short term sentiment regarding the housing market shouldn't move the price of REA as much as it does, but therein lies the opportunity for us as investors. The fall in the stock price last year in a weak property market allowed us to enter the stock at reasonable price, which is now paying off.

The equal two biggest detractors this month were IDP Education and Healthia (ASX: IEL and HLA) which fell 5%

and 11% respectively. Neither had any significant news. IEL remains well placed to benefit from the growth in demand for international student placement and English language testing. Healthia's underlying growth has normalised post Covid and they continue to make sensible bolt on acquisitions.

We continue to identify compelling investment opportunities. We have seen in the past that as our companies execute on their business opportunities, the market will eventually recognise this in their share prices. This is what has driven our longer term investment returns namely, our ability to continue to identify compelling opportunities.

### **Return Summary**<sup>1</sup> (after all fees)

l Month	3 Months
-0.90%	-1.10%
l Year	3 Years
-4.30%	+20.20%

This fund is appropriate for investors with "High" and "Very High" risk and return profiles. A suitable investor for this fund is prepared to accept high risk in the pursuit of capital growth with a medium to long investment timeframe. Investors should refer to the TMD for further information.







<sup>&</sup>lt;sup>1.</sup> Inception date is 2 July 2012. Past performance is not indicative of future performance.



# Monash Absolute Investment Fund (APIR MON0001AU)

Monthly Portfolio Metrics		
Outlook Stocks (Long)	15 Positions: 70%	
Outlook Stocks (Short)	1 Positions: -3%	
Event, Pair and Group (Long)	2 Positions: 16%	
Event, Pair and Group (Short)	1 Positions: -1%	
Cash	9%	
Gross Exposure	89%	
Net Exposure	81%	

Portiono Analytics Since inception-	
Sharpe Ratio	0.49
Sortino Ratio	0.86
Standard Deviation (p.a.)	16%
Positive Months	60%
Maximum Drawdown	-29%
Avg. Gross Exposure	91%
Avg. Net Exposure	79%
Avg. Beta	0.68

Return Summary Since Inception (after fees) <sup>2</sup>		
CYTD	-1.11%	
FYTD	2.77%	
1 Month	-0.88%	
3 Month	-1.11%	
6 Month	2.41%	
1 Year	-4.30%	
2 Years (p.a.)	-3.16%	
3 Years (p.a.)	20.15%	
4 Years (p.a.)	11.34%	
5 Years (p.a.)	9.16%	
7 Years (p.a.)	6.83%	
Since Inception (p.a.)	9.61%	







<sup>&</sup>lt;sup>2.</sup> Inception date 2 July 2012. Past performance is not indicative of future performance.



# Monash Absolute Investment Fund (APIR MON0001AU)

#### For all business development enquiries, please contact

Cameron Harris
P: +61 400 248 435
cameron@gsmcapital.com.au

#### For all investors enquiries, please contact

Apex Fund Services Pty Ltd,

P: 1300 133 451

or by email at registry@apexgroup.com

For more information about MAIF and the strategy, please refer to the Monash Investors website at <a href="https://www.monashinvestors.com">www.monashinvestors.com</a>. You can also follow us on Livewire here or subscribe to our updates here

This document is prepared by Monash Investors Pty Limited ABN 67 153 180 333, AFSL 417 201 ("Monash Investors") as authorised representatives of Sanlam Private Wealth Pty Ltd ABN 18 136 960 775, AFSL 337 927 ("Sanlam") for the provision of general financial product advice in relation to the Monash Absolute Investment Fund ARSN 606 855 501 ("Fund") and authorised for release by The Trust Company (RE Services) Limited ABN 45 003 278 831, AFSL 235 150 ("Perpetual") as the responsible entity of, and issuer of units in the Fund. Monash Investors is the investment manager of the Fund. A Product Disclosure Statement ("PDS") dated 25 May 2022 together with a Target Market Determination ("TMD"), both issued by Perpetual, is available for the Fund at <a href="https://www.monashinvestors.com">www.monashinvestors.com</a>. You should obtain and consider the PDS and TMD for the Fund before deciding whether to acquire, or continue to hold, an interest in the Fund. The information provided is general information only and is not intended to provide you with financial advice, it does not consider your investment objectives, financial situation or particular needs. You should consider your own investment objectives, financial situation and particular needs before acting upon any information provided and consider seeking advice from a financial advisor if necessary. To the extent permitted by law, no liability is accepted for any loss or damage as a result of any reliance on this information. No company in Perpetual Circup (Perpetual Limited ABN 86 000 431 827 and its subsidiaries) guarantees the performance of any fund or the return of an investor's capital.

Performance figures assume reinvestment of income. Past performance is not a reliable indicator of future performance. Comparisons are provided for information purposes only and are not a direct comparison against benchmarks or indices that have the same characteristics as the Fund. Monash Investors, Sanlam and Perpetual do not guarantee repayment of capital or any particular rate of return from the Fund and do not give any representation or warranty as to the reliability, completeness or accuracy of the information contained in this document. All opinions and estimates included in this document constitute judgments of Monash Investors as at the date of this document are subject to change without notice. Perpetual is not responsible for this document.

In relation to the target distribution, this is a target return only. There is no guarantee the Fund will meet its investment objective. The payment of a quarterly distribution is a goal of the Fund only and neither Monash Investors or Perpetual provide any representations or warranty (whether express or implied) in relation to the payment of any quarterly cash income. The Fund reserves the discretion to amend its distribution policy.

The rating issued 09/2021 is published by Lonsec Research Pty Ltd ABN 11 151 658 561 AFSL 421 445 (Lonsec). Ratings are general advice only, and have been prepared without taking account of your objectives, financial situation or needs. Consider your personal circumstances, read the product disclosure statement and seek independent financial advice before investing. The rating is not a recommendation to purchase, sell or hold any product. Past performance information is not indicative of future performance. Ratings are subject to change without notice and Lonsec assumes no obligation to update. Lonsec uses objective criteria and receives a fee from the Fund Manager. Visit lonsec.com.au for ratings information and to access the full report. © 2020 Lonsec. All rights reserved.

The rating contained in this document is issued by SQM Research Pty Ltd ABN 93 122 592 036 AFSL 421913. SQM Research is an investment research firm that undertakes research on investment products exclusively for its wholesale clients, utilising a proprietary review and star rating system. The SQM Research star rating system is of a general nature and does not take into account the particular circumstances or needs of any specific person. The rating may be subject to change at any time. Only licensed financial advisers may use the SQM Research star rating system in determining whether an investment is appropriate to a person's particular circumstances or needs. You should read the product disclosure statement and consult a licensed financial adviser before making an investment decision in relation to this investment product. SQM Research receives a fee from the Fund Manager for the research and rating of the managed investment scheme.

The Zenith Investment Partners (ABN 27 103 132 672, AFS Licence 226872) ("Zenith") rating (assigned MON0001AU June 2021) referred to in this document is limited to "General Advice" (s766B Corporations Act 2001) for Wholesale clients only. This advice has been prepared without taking into account the objectives, financial situation or needs of any individual and is subject to change at any time without prior notice. It is not a specific recommendation to purchase, sell or hold the relevant product(s). Investors should seek independent financial advice before making an investment decision and should consider the appropriateness of this advice in light of their own objectives, financial situation and needs. Investors should obtain a copy of and consider the PDS or offer document before making any decision and refer to the full Zenith Product Assessment available on the Zenith website. Past performance is not an indication of future performance. Zenith usually charges the product issuer, fund manager or related party to conduct Product Assessments. Full details regarding Zenith's methodology, ratings definitions and regulatory compliance are available on our Product Assessments and at http://www.zenithpartners.com.au/RegulatoryGuidelines.





